PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26588239-11	2016	CONCLUSIONS: Patients with TOP2A overexpression have a worse prognosis compared with those with TOP2A nonexpression, and TOP2A may be a useful biomarker in patients receiving adjuvant taxane-platinum regimens with moderate- to high-risk endometrial cancer.	taxane	184-190	DNA topoisomerase II alpha	Homo sapiens	27-32	
26588239-0	2016	Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy.	taxane	71-77	DNA topoisomerase II alpha	Homo sapiens	14-19	
26588239-3	2016	In the present study, we performed a retrospective investigation of the association between TOP2A, HER2 overexpression, and disease-free and overall survival in patients with endometrial cancer receiving taxane and platinum.	taxane	204-210	DNA topoisomerase II alpha	Homo sapiens	92-97	
22441341-1	2013	INTRODUCTION: The primary aim of this study is to investigate the effect of change in the expression levels of survivin, glutathione-S-transferase P1 (GSTP1), and topoisomerase 2alpha (TOP2A) on the response to antracyclin-based and taxane-based neoadjuvant chemotherapy.	taxane	233-239	DNA topoisomerase II alpha	Homo sapiens	185-190	
22016618-7	2011	Amplified TOP2A, TAU and RDM1 genes are related to a significant response to anthracycline-based chemotherapy, taxane or cisplatin, respectively.	taxane	111-117	DNA topoisomerase II alpha	Homo sapiens	10-15